Spero Therapeutics, Inc.SPRONASDAQ
LOADING
|||
Switch Symbol:
Revenue Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year revenue growth rate
Latest
-74.17%
↓ 133% below average
Average (36q)
222.66%
Historical baseline
Range
High:4184.10%
Low:-95.54%
Volatility
1922.1%
High variability
| Period | Value |
|---|---|
| Q3 2025 | -74.17% |
| Q2 2025 | 100.92% |
| Q1 2025 | -60.95% |
| Q4 2024 | 11.69% |
| Q3 2024 | 32.09% |
| Q2 2024 | 142.55% |
| Q1 2024 | -94.28% |
| Q4 2023 | 188.63% |
| Q3 2023 | 837.89% |
| Q2 2023 | 31.27% |
| Q1 2023 | -95.54% |
| Q4 2022 | 4184.10% |
| Q3 2022 | 20.76% |
| Q2 2022 | 262.75% |
| Q1 2022 | -91.00% |
| Q4 2021 | 287.57% |
| Q3 2021 | -66.38% |
| Q2 2021 | -71.15% |
| Q1 2021 | 282.80% |
| Q4 2020 | -52.27% |
| Q3 2020 | 131.33% |
| Q2 2020 | 1.53% |
| Q1 2020 | -53.14% |
| Q4 2019 | 2010.47% |
| Q3 2019 | -92.02% |
| Q2 2019 | -43.37% |
| Q1 2019 | 125.00% |
| Q4 2018 | 157.14% |
| Q3 2018 | 42.12% |
| Q2 2018 | -59.84% |
| Q1 2018 | 16.11% |
| Q4 2017 | 66.33% |
| Q3 2017 | 139.76% |
| Q2 2017 | 77.86% |
| Q1 2017 | -58.21% |
| Q4 2016 | 0.00% |
| Q3 2016 | 0.00% |